Sacramento Bee1d
MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study
Non-Habit Forming: Unlike Pregabalin, Ketamir-2 carries no known risk of dependence, making it safer for long-term use. Fewer ...
MIRA says Ketamir-2 outperforms FDA-approved neuropathic pain treatments
MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved ...
Zacks Small Cap Research on MSN23h
MIRA Continues to Post Outstanding Test Results
MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...
Morningstar1mon
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Ketamir-2 is MIRA's response to this pressing market need-a novel ketamine analog designed to enhance therapeutic efficacy, improve oral bioavailability, and offer a superior safety profile ...
Benzinga.com24d
Why Mira Shares Are Trading Higher Today
MIRA shares surge 10.3% after new preclinical data shows Ketamir-2 achieves 100% reversal of neuropathic pain. Ketamir-2 presentation set for October's Pain Therapeutics Summit, highlighting its ...
Yahoo Finance14d
MIRA PHARMACEUTICALS INC. (K6S.BE)
As of 6:35 PM GMT+2. Market Open. Conference presentation delivers preclinical results demonstrating Ketamir-2 achieves 100% reversal of neuropathic pain MIAMI, FL / ACCESSWIRE / September 27 ...
Merced Sun-Star1mon
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
Neuropathic pain is a complex and debilitating condition caused by a variety of causes, induced by damage or dysfunction of the nervous system. It often presents as burning, electric shocks, or ...
WSIL-TV1mon
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
MIAMI, FL / ACCESSWIRE / September 11, 2024 / MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a preclinical-stage pharmaceutical company focused on developing innovative therapies for neurologic and ...